Overview

This trial is active, not recruiting.

Conditions pancreatic cysts, pancreatic cancer
Sponsor Johns Hopkins University
Collaborator Lustgarten Foundation
Start date October 2012
End date January 2017
Trial size 450 participants
Trial identifier NCT01202136, NA_00026447

Summary

The aim is to propose and prospectively validate a diagnostic approach and model for prediction of mucinous versus non-mucinous, and malignant versus non-malignant pancreatic cysts using a combination of clinical, radiologic, and biomarker characteristics.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
patients referred to Johns Hopkins Hospital for evaluation and or treatment for 1 or more pancreatic cysts

Primary Outcomes

Measure
Prevalence and incidence of malignant pancreatic cysts
time frame: 3-6 years

Secondary Outcomes

Measure
Biomarkers to predict type of pancreatic cyst
time frame: 3-6 years
Biomarker panel in pancreatic juice as indicator to type of pancreatic cyst
time frame: 3-6 years
Compare CT with EUS and MRI for diagnosing pancreatic cysts.
time frame: 3-6 year
Difference EUS/CT or MRCP in diagnosis of malignant pancreatic cysts
time frame: 3-6 years
Associated factors for with multivariate model for malignant pancreatic cyst
time frame: 3-6 years
Model for prediction of malignant pancreatic cysts
time frame: 3-6 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Adult patients age 18 years and older 2. Referred for assessment of one or more pancreatic cyst. Exclusion Criteria: 1. Medically ill patients with ASA class 4 or greater. 2. History of chronic kidney disease with a serum creatinine > 2.0 mg/dl or estimated glomerulofiltration rate (eGFR) < 30 ml/min, dialysis patients, acute renal failure, cirrhosis of the liver, chronic hepatitis, prior nephrectomy or kidney or liver transplantation. 3. History of moderate (generalized hives) or severe (facial swelling, airway reaction) reaction to intravenous radiographic contrast material. 4. History of obstruction in the upper GI tract such as esophageal or pyloric stricture, which would not allow passage of an endoscope. 5. Bleeding diathesis (clotting problems) or a history of thrombocytopenia (low platelet count <50,000). 6. Inability to provide informed consent. 7. Pregnancy or lactation.

Additional Information

Official title The Clinical,Radiologic, Pathologic and Molecular Marker Characteristics of Premalignant and Malignant Pancreatic Cysts Study
Principal investigator Anne Marie O'Broin-Lennon, MD
Description This combined cross-sectional and prospective single center clinical and translational study involves a collaborative multidisciplinary team composed of gastroenterologists, surgeons, radiologists, and basic scientists. Eligible patients with solitary or multiple pancreatic cysts referred for diagnostic evaluation and/or surgical treatment will undergo initial radiographic imaging with high-resolution CT, MRI/MRCP, and EUS/FNA as part of standard medical care at Johns Hopkins Hospital. This is a three-phase study. In Phase I, eligible patients with pancreatic cysts will undergo initial radiographic imaging (high-resolution CT, MRI/MRCP, endoscopic ultrasonography (EUS) with fine needle aspiration (FNA)) as part of standard care at the Johns Hopkins Hospital. Patients will be categorized according to the presence of symptoms referable to the cyst or imaging features concerning for malignancy based on the initial radiographic assessment. Symptomatic patients, or those with concerning features, will be referred for surgical resection. The pathologic features and final diagnosis of resected pancreatic cysts will be compared with preoperative clinical, radiologic, and cyst fluid test results. Asymptomatic patients with low-risk features at baseline radiographic and endoscopic imaging will enter Phase II. Patients will be followed on a prospective periodic surveillance schedule according the consensus clinical guidelines with either CT or MRI to monitor for new or metachronous cystic neoplasms. Those who develop symptoms or concerning features will have a repeat EUS/FNA as well as imaging with the opposite axial imaging modality, and will be referred for surgery if a suspicious lesion is detected. Patients who have surgery either during Phase I or Phase II, will enter post-surgical surveillance (Phase III). Patients will be followed using a prospective periodic surveillance schedule according the consensus clinical guidelines with either CT or MRI to monitor for new or metachronous cystic neoplasms. Those who undergo surgery after surveillance in Phase II will continue with the imaging modality they were originally evaluated with prior to surgery.. Patients who develop symptoms or high-risk features on imaging will have a repeat EUS/FNA as well as imaging with the opposite axial imaging modality and will be referred for surgery if a suspicious lesion is detected. Samples will be collected prospectively for biomarker analysis. Cyst fluid, pancreatic juice and blood will be collected during EUS and blood will be collected yearly during the outpatient clinic visit. Patients will be followed for three years.
Trial information was received from ClinicalTrials.gov and was last updated in October 2016.
Information provided to ClinicalTrials.gov by Johns Hopkins University.